Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.58 |
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | FPR2 | P25090 | 2/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195536 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL30229505 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL29364294 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL30873956 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL3230124 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL31369852 | 0.97 | MDM2 (0.60) | MDM2MDM4TP53FPR2CASP3 | |
| SCHEMBL118169 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL1228254 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL119455 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL30291593 | 0.92 | MDM4 (0.59) | MDM2MDM4TP53CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050248-A1 | Novel amino acid and peptide inhibitors of Staphylococcus virulence | PANORAMA RESEARCH, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1261362-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | Intermune, Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | claimed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | NEW YORK UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-3303367-B1 | STABILIZED MINIMAL COILED-COIL MIMETICS | UNIV NEW YORK (US) | 2025-06-18 | — | — | EP | disclosed |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | Bicyclerd Limited (GB) | 2025-06-03 | — | — | US | disclosed |
| EP-3452096-B1 | BICYCLIC PEPTIDE-TOXIN CONJUGATES SPECIFIC FOR MT1-MMP | BICYCLERD LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | disclosed |
| US-6420396-B1 | TREATMENT OF CANCER, ARTERIOSCLEROSIS, RESTENOSIS, OSTEOLYTIC DISORDERS, OPHTHALMIC DISORDERS, AND THEIR USE AS INTEGRIN ANTAGONISTS. INHIBITING ANGIOGENESIS | BEIERSDORF AG (DE) | 2002-07-16 | — | — | US | disclosed |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | US | disclosed |
| EP-1140809-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| WO-2001047887-A1 | β-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000035864-A1 | NEW BIPHENYL AND BIPHENYL-ANALOGOUS COMPOUNDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999065932-A1 | TETRAPEPTIDES, ANALOGS AND PEPTIDOMIMETICS WHICH BIND SELECTIVELY MAMMALIAN OPIOID RECEPTORS | SEPRACOR, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | COIL, CALCOCO2, NCAPH | MDM2 777/4885MDM4 2743/4885TP53 3446/4885 |
| US-20250230191-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | MDM2 2867/4885MDM4 3415/4885TP53 3318/4885 |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | MDM2 1933/4885MDM4 2089/4885TP53 826/4885 |
| US-20020016461-A1 | Biphenyl and biphenyl-analogous compounds as integrin antagonists | ITGB1, ITGB2, ITGB3 | MDM2 1959/4885MDM4 4085/4885TP53 3256/4885 |
| US-12318454-B2 | Bicyclic peptide ligands specific for MT1-MMP | MMEL1, MMP3, TIMP3 | MDM2 1933/4885MDM4 2089/4885TP53 826/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | MDM2 908/4885MDM4 2407/4885TP53 2772/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | MDM2 164/4885MDM4 441/4885TP53 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.